Skip to main content

Peer Review reports

From: Management of metastatic melanoma in Texas: disparities in the utilization of immunotherapy following the regulatory approval of immune checkpoint inhibitors

Original Submission
29 Dec 2022 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
24 May 2023 Reviewed Reviewer Report
25 May 2023 Reviewed Reviewer Report
3 Jun 2023 Reviewed Reviewer Report
13 Jun 2023 Author responded Author comments - Ekere James Essien
Resubmission - Version 4
13 Jun 2023 Submitted Manuscript version 4
20 Jun 2023 Reviewed Reviewer Report
23 Jun 2023 Reviewed Reviewer Report
30 Jun 2023 Reviewed Reviewer Report
Resubmission - Version 5
Submitted Manuscript version 5
Publishing
30 Jun 2023 Editorially accepted
13 Jul 2023 Article published 10.1186/s12885-023-11142-4

You can find further information about peer review here.

Back to article page